Scribe Therapeutics preps IPO to fund lipid‑lowering genetic medicines through clinical trials

California-based biotech Scribe Therapeutics has filed for an initial public offering (IPO) on the Nasdaq, aiming to raise up to about $75 million under the ticker symbol SCTX.

The company plans to use IPO proceeds, along with its existing cash, to fund clinical development of its lead lipid-lowering candidate STX‑1150 and other programs targeting cardiometabolic disease.

STX‑1150 is an in vivo CRISPR-based, epigenetic silencer of PCSK9 designed to deliver durable LDL‑C reductions without permanently altering DNA; it is currently in a first‑in‑human trial in Australia, with initial data expected in the first half of 2027.

Scribe also plans to advance STX‑1200 (targeting Lp(a)) and STX‑1400 (targeting APOC3/triglycerides) into first‑in‑human studies starting in 2027 and 2028, helped by recent multi‑million‑dollar funding from the California Institute for Regenerative Medicine (CIRM).

The IPO is viewed as a test of investor appetite for earlier‑stage biotechs, as Scribe’s programs are still in early clinical and preclinical stages despite targeting widespread cardiovascular risk factors that affect millions of people.